Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2014 (2014), Article ID 236310, 10 pages
http://dx.doi.org/10.1155/2014/236310
Research Article

Safety of Intravenous Application of Mistletoe (Viscum album L.) Preparations in Oncology: An Observational Study

1Research Institute Havelhoehe, 14089 Berlin, Germany
2Hospital Havelhoehe, 14089 Berlin, Germany
3Institute for Social Medicine, Epidemiology and Health Economics, Charité-University Medical Centre, 10117 Berlin, Germany
4Institute of Integrative Medicine, Witten/Herdecke University, 58313 Herdecke, Germany

Received 21 November 2013; Revised 2 April 2014; Accepted 3 April 2014; Published 15 May 2014

Academic Editor: Srini Kaveri

Copyright © 2014 Megan L. Steele et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. A. Horneber, G. Bueschel, R. Huber, K. Linde, and M. Rostock, “Mistletoe therapy in oncology,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD003297, 2008. View at Google Scholar · View at Scopus
  2. M. Mabed, L. El-Helw, and S. Shamaa, “Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma,” British Journal of Cancer, vol. 90, no. 1, pp. 65–69, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Orange, M. Fonseca, A. Lace, H. B. von Laue, and S. Geider, “Durable tumour responses following primary high dose induction with mistletoe extracts: two case reports,” European Journal of Integrative Medicine, vol. 2, no. 2, pp. 63–69, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Huber, H. Barth, A. Schmitt-Gräff, and R. Klein, “Hypereosinophilia induced by high-dose intratumoral and peritumoral mistletoe application to a patient with pancreatic carcinoma,” Journal of Alternative and Complementary Medicine, vol. 6, no. 4, pp. 305–310, 2000. View at Google Scholar · View at Scopus
  5. F. Schad, J. Axtner, D. Buchwald et al., “Intratumoral mistletoe (Viscum album L) therapy in patients with unresectable pancreas carcinoma: a retrospective analysis,” Integrative Cancer Therapies, 2013. View at Publisher · View at Google Scholar
  6. M. Orange, Mistletoe therapy for cancer patients [M.S. thesis], University of Birmingham, 2010, http://www.anthromed.org/.
  7. I. F. Pryme, S. Bardocz, A. Pusztai, and S. W. B. Ewen, “Suppression of growth of tumour cell lines in vitro and tumours in vivo by mistletoe lectins,” Histology and Histopathology, vol. 21, no. 1–3, pp. 285–299, 2006. View at Google Scholar · View at Scopus
  8. T. J. Yoon, Y. C. Yoo, O. B. Choi et al., “Inhibitory effect of Korean mistletoe (Viscum album coloratum) extract on tumour angiogenesis and metastasis of haematogenous and non-haematogenous tumour cells in mice,” Cancer Letters, vol. 97, no. 1, pp. 83–91, 1995. View at Publisher · View at Google Scholar · View at Scopus
  9. K. S. Zaenker, H. Matthes, P. R. Bock, and J. Hanisch, “A specific mistletoe preparation (Iscador-Qu) in colorectal cancer (CRC) patients: more than just supportive care?” Journal of Cancer Science & Therapy, vol. 4, no. 9, pp. 264–270, 2012. View at Publisher · View at Google Scholar
  10. S. Elluru, J.-P. D. van Huyen, B. Wootla et al., “Tumor regressive effects of Viscum album preparations. Exploration of immunomodulatory mechanisms,” Medicina, vol. 67, supplement 2, pp. 85–89, 2007. View at Google Scholar · View at Scopus
  11. J. Kuehn, “Different routes of application in mistletoe therapy—effect on bone marrow and blood profile. Clinical significance,” Phytomedicine, vol. 18, supplement 1, p. S11, 2011. View at Publisher · View at Google Scholar
  12. R. Zerm, M. Kröz, and H. Matthes, “Treatment of a patient suffering from advanced colorectal carcinoma with intravenous mistletoe application and Ardalan-chemotherapy,” in Fortschritte in der Misteltherapie: Aktueller Stand der Forschung und Klinische Anwendung, R. Scheer, R. Bauer, H. Becker, V. Fintelmann, F. H. Kemper, and H. Schilcher, Eds., KVC, Essen, Germany, 2005. View at Google Scholar
  13. F. Schad, M. Kröz, M. Girke, H.-P. Lemmens, D. Brauer, and B. Matthes, “Intraläsionale und kombinierte subkutan-intravenöse Misteltherapie bei einem Patienten mit Kolonkarzinom,” Der Merkurstab, vol. 52, no. 6, pp. 399–406, 1999. View at Google Scholar
  14. J. Pieper, “Der Einsatz von Plenosol bei inoperablen Tumoren,” EHK, vol. 9, pp. 547–549, 1987. View at Google Scholar
  15. G. Spahn, V. Schindler, C. Heyder et al., “Integrative Behandlung des Pankreaskarzinoms unter Verwendung von Viscum-Präparaten—Ergebnisse aus dem klinischen Register der Klinik Öschelbronn 2007–2010,” in Die Mistel in der Tumortherapie 3—Aktueller Stand der Forschung und klinische Anwendung, R. Scheer, S. Alban, H. Becker, and R. Stange, Eds., pp. 265–278, KVC, Essen, Germany, 2013. View at Google Scholar
  16. P. Wolf, N. Freudenberg, and M. Konitzer, “Analgetische und stimmungsaufhellende Wirkung bei Malignom-Patienten unter hochdosierter Viscum album-Infusionstherapie (Vysorel),” Deutsche Zeitschrift für Onkologie, vol. 26, pp. 52–54, 1994. View at Google Scholar
  17. M. Girke, Innere Medizin: Grundlagen und therapeutische Konzepte der Anthroposophischen Medizin, Salumed, Berlin, Germany, 2010.
  18. A. Büssing, U. Bückner, U. Enser-Weis et al., “Modulation of chemotherapy-associated immunosuppression by intravenous application of Viscum album L. extract, (Iscador): a randomised phase II study,” European Journal of Integrative Medicine, vol. 1, supplement 1, pp. 2–3, 2008. View at Google Scholar
  19. A. Büssing, “Immune modulation using mistletoe (Viscum album L.) extracts Iscador: influencing cell function through subcutaneous and intravenous application,” Arzneimittel-Forschung, vol. 56, no. 6A, pp. 508–515, 2006. View at Google Scholar · View at Scopus
  20. M. Schink, W. Tröger, A. Dabidian et al., “Mistletoe extract reduces the surgical suppression of natural killer cell activity in cancer patients. A randomized phase III trial,” Forschende Komplementarmedizin, vol. 14, no. 1, pp. 9–17, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Büssing, M. Bischof, W. Hatzmann et al., “Beeinflussung der Granulozytenfunktion durch einmalige perioperative Mistelextrakt-Infusion,” Deutsche Zeitschrift für Onkologie, vol. 36, no. 4, pp. 148–153, 2004. View at Google Scholar
  22. M. Cazacu, T. Oniu, C. Lungoci et al., “The influence of Isorel on the advanced colorectal cancer,” Cancer Biotherapy and Radiopharmaceuticals, vol. 18, no. 1, pp. 27–34, 2003. View at Google Scholar · View at Scopus
  23. J. Beuth, B. Schneider, and J. M. Schierholz, “Impact of complementary treatment of breast cancer patients with standardized mistletoe extract during aftercare: a controlled multicenter comparative epidemiological cohort study,” Anticancer Research, vol. 28, no. 1B, pp. 523–527, 2008. View at Google Scholar · View at Scopus
  24. J. Eisenbraun, R. Scheer, M. Kröz, F. Schad, and R. Huber, “Quality of life in breast cancer patients during chemotherapy and concurrent therapy with a mistletoe extract,” Phytomedicine, vol. 18, no. 2-3, pp. 151–157, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. P. J. Mansky, D. B. Wallerstedt, T. S. Sannes et al., “NCCAM/NCI phase 1 study of mistletoe extract and Gemcitabine in patients with advanced solid tumors,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 964592, 11 pages, 2013. View at Publisher · View at Google Scholar
  26. F. Schad, J. Axtner, A. Happe et al., “Network oncology (NO)—a clinical cancer register for health services research and the evaluation of integrative therapeutic interventions in anthroposophic medicine,” Forschende Komplementärmedizin, vol. 20, no. 5, pp. 369–375, 2013. View at Publisher · View at Google Scholar
  27. M. L. Steele, J. Axtner, A. Happe, M. Kröz, H. Matthes, and F. Schad, “Adverse drug reactions and expected effects to therapy with subcutaneous mistletoe extracts (Viscum album L.) in cancer patients,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 724258, 11 pages, 2014. View at Publisher · View at Google Scholar
  28. F. Schad, C. Teodoridis, U. Albrecht et al., “Network Oncology (NO)—a European approach to health service research on cancer treatment with focus on concurrent use of complementary therapies,” European Journal of Integrative Medicine, vol. 1, no. 1, pp. 12–13, 2008. View at Publisher · View at Google Scholar
  29. F. Schad, J. Pissarek, U. Albrecht, and H. Matthes, “QuaDoSta (quality assurance, documentation and statistics)—a flexible, platform-independent, open source database for oncological documentation,” Cancer Research and Clinical Oncology, vol. 130, supplement op, p. 785, 2004. View at Google Scholar
  30. J. M. M. Evans, D. McNaughton, P. T. Donnan, and T. M. MacDonald, “Pharmacoepidemiological research at the Medicines Monitoring Unit, Scotland: data protection and confidentiality,” Pharmacoepidemiology and Drug Safety, vol. 10, no. 7, pp. 669–673, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, R Core Team, Vienna, Austria, 2012.
  32. ICH, E2A: Clinical safety data management: definitions and standards for expedited reporting, http://www.ich.org/.
  33. UMC, Safety monitoring of medicinal products: guidelines for setting up and running a pharmacovigilance centre, http://www.who.int/medicinedocs.
  34. CTEP, Common Terminology Criteria for Adverse Events, http://ctep.cancer.gov/protocolDevelopment/.
  35. “Mistletoe products from Helixor,” 2014, http://www.helixor.com/integrative-cancer-therapy/mistletoe-therapy/products/.
  36. Mistletoe therapy: patient information, 2014, http://www.abnoba.com/start.aspx.
  37. R. Wagner, Praktische Prüfungsmethoden zur Beurteilung der Misteltherapie: ein Leitfaden für den niedergelassenen Arzt. Beiträge zur Krebstherapie, Urachhaus, Stuttgart, Germany, 1994.
  38. “Iscador,” March 2014, http://allgemein.mistel-therapie.de/index.php5?page=39&lang=1.
  39. Y. Zopf, C. Rabe, A. Neubert et al., “Women encounter ADRs more often than do men,” European Journal of Clinical Pharmacology, vol. 64, no. 10, pp. 999–1004, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. N. Rouas-Freiss, P. Moreau, C. Menier, and E. D. Carosella, “HLA-G in cancer: a way to turn off the immune system,” Seminars in Cancer Biology, vol. 13, no. 5, pp. 325–336, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. L. Rasmussen and A. Arvin, “Chemotherapy-induced immunosuppression,” Environmental Health Perspectives, vol. 43, pp. 21–25, 1982. View at Google Scholar · View at Scopus
  42. R. J. Wills, S. Dennis, and H. E. Spiegel, “Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection,” Clinical Pharmacology and Therapeutics, vol. 35, no. 5, pp. 722–727, 1984. View at Google Scholar · View at Scopus
  43. M. McDonald and D. J. Sexton, Drug Fever. UpToDate, 2012, http://www.uptodate.com/contents/drug-fever#H11.
  44. P. Schöffski, S. Riggert, P. Fumoleau et al., “Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group,” Annals of Oncology, vol. 15, no. 12, pp. 1816–1824, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. R. Huber, J. Eisenbraun, B. Miletzki et al., “Pharmacokinetics of natural mistletoe lectins after subcutaneous injection,” European Journal of Clinical Pharmacology, vol. 66, no. 9, pp. 889–897, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. C. A. Jacobs, D. H. Lynch, E. R. Roux et al., “Characterization and pharmacokinetic parameters of recombinant soluble interleukin-4 receptor,” Blood, vol. 77, no. 11, pp. 2396–2403, 1991. View at Google Scholar · View at Scopus
  47. N. Hayashi, H. Kinoshita, E. Yukawa, and S. Higuchi, “Pharmacokinetic analysis of subcutaneous erythropoietin administration with nonlinear mixed effect model including endogenous production,” British Journal of Clinical Pharmacology, vol. 46, no. 1, pp. 11–19, 1998. View at Publisher · View at Google Scholar · View at Scopus
  48. K. R. Wiebelitz and A. M. Beer, “High dose intravenous mistletoe treatment—clinical results, laboratory findings and adverse events in a series of 17 patients with 107 intravenous applications,” Phytomedicine, vol. 18, supplement 1, p. S11, 2011. View at Google Scholar
  49. P. Wolf, “Die Mistel-Infusionstherapie zur Behandlung von Tumorleiden,” Naturamed, vol. 4, no. 12, pp. 720–724, 1989. View at Google Scholar
  50. G. S. Kienle, Verträglichkeit, Nebenwirkungen, Überempfindlichkeitsreaktionen, Toxizität, Wissenschaftliche Informationen, 2005, http://wissenschaft.mistel-therapie.de/index.php5?page=57.